Skip to content

Blog Articles

Blog Articles

XLK ETF Factor Report

Below is Validea’s ETF fundamental report for SPDR Technology Select Sector SPDR Fund (XLK). The report looks at XLK’s exposure to the major investing factors including value, quality, momentum and low volatility.
SPDR Technology Select Sector SPDR Fund (XLK) is a Large-Cap

China’s new anti-involution fight is less punchy than 2015 reform, analysts say

China’s intensified fight against cutthroat, low-quality price competition – known as involution – is unlikely to result in supply-side reform of the same magnitude as such reform in 2015, as the world’s second-largest economy lacks the mettle to cut production capacity or add consumption stimulus, according to an economic research firm.
Investors have been quick to draw parallels between recent and earlier meetings of the Central Committee of Financial and Economic Affairs (CCFEA) that became…

China’s biotech industry is gaining on the US. Can tariffs hold them back?

In the summer of 2015, a time when China’s pharmaceutical market was in a phase of rapid expansion, a sudden regulatory change sent tremors through the industry: drug companies would need to audit the clinical trial data for all pending applications.
If withdrawn within a month of the announcement, firms could avoid penalties for submitting flawed applications, but hiding or falsifying data would court severe punishments, including multi-year filing bans.
The response from the industry indicated…
What are you looking for?